Air Qual Atmos Health by Gronlund, Carina J. et al.
Characterizing the burden of disease of particulate matter for life 
cycle impact assessment
Carina J. Gronlund1, Sebastien Humbert2, Shanna Shaked3, Marie S. O’Neill1, and Olivier 
Jolliet1
1University of Michigan School of Public Health, Ann Arbor, Michigan 2Quantis, Lausanne, 
Switzerland 3University of California, Los Angeles, Physics and Astronomy, Los Angeles, 
California
Abstract
Fine particulate air pollution (PM2.5) is a major environmental contributor to human burden of 
disease and therefore an important component of life cycle impact assessments. An accurate PM2.5 
characterization factor, i.e., the impact per kg of PM2.5 emitted, is critical to estimating “cradle-to-
grave” human health impacts of products and processes. We developed and assessed new 
characterization factors (disability-adjusted life years (DALY)/kgPM2.5 emitted), or the products of 
dose-response factors (deaths/kgPM2.5 inhaled), severity factors (DALY/death) and intake fractions 
(kgPM2.5 inhaled/kgPM2.5 emitted). In contrast to previous health burden estimates, we calculated age-
specific concentration- and dose-response factors using baseline data, from 63 U.S. metropolitan 
areas, consistent with the U.S. study population used to derive the relative risk. We also calculated 
severity factors using 2010 Global Burden of Disease data. Multiplying the revised PM2.5 dose-
responses, severity factors and intake fractions yielded new PM2.5 characterization factors that are 
higher than previous factors for primary PM2.5 but lower for secondary PM2.5 due to NOx. 
Multiplying the concentration-response and severity factors by 2005 ambient PM2.5 
concentrations yielded an annual U.S. burden of 2,000,000 DALY, slightly lower than previous 
U.S. estimates. The annual U.S. health burden estimated from PM emissions and characterization 
factors was 2.2 times higher.
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1. INTRODUCTION
Life cycle impact assessment (LCIA) evaluates the impact of a product or process from 
“cradle to grave”—from the extraction of the natural resources used to make the product to 
its disposal. A product or process usually generates particulate matter (PM) air pollution, 
either through the vehicular transport of the product or through the use of electricity from 
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fossil-fueled power plants in the manufacture or use of the product. PM is classified as 
“primary” when it is emitted directly and “secondary” when it forms in the atmosphere due 
to secondary chemical reactions between other airborne substances. Whether primary or 
secondary, an accurate characterization factor for PM, defined as the disability-adjusted life 
years (DALY, or years of healthy life lost) per kg particulate emitted, is critical to the 
analysis of health impacts in LCIAs.
Long-term epidemiologic cohort studies examining the association between PM and 
mortality in the U.S. provide effect estimates preferable to those derived from animal studies 
for use in calculating a PM characterization factor. Many such studies, including the 
Harvard Six Cities Study (Laden et al. 2006) and the American Cancer Society Study of 
Particulate Air Pollution and Mortality (Pope et al. 2002) found increased mortality with 
increasing concentrations of PM (Hoek et al. 2013). These two studies in particular have 
informed the U.S. Environmental Protection Agency’s National Ambient Air Quality 
Standards for PM, which are intended to protect population health.
In the specific LCIA context, Hofstetter (1998) provided an initial set of characterization 
factors for the primary and secondary PM impacts per kg emitted, in terms of DALY. The 
definition of a characterization factor was further formalized as the product of an intake 
fraction (Jolliet et al. 2003) multiplied by an effect factor that consists of a dose-response 
and severity factor, enabling the comparison of PM impacts with other organic and 
inorganic pollutants. Van Zelm et al. (2008) updated this framework, calculating a 
particulate characterization factor using results from epidemiologic studies of PM less than 
ten microns in aerodynamic diameter (PM10)-associated health effects, some conducted in 
the U.S. (Dockery et al. 1993; Pope et al. 1995), in conjunction with models of particulate 
exposure and demographic data from Europe.
Although that study significantly improved the quality of characterization factors used in 
LCIA, we have developed a new approach addressing three issues related to the key inputs 
to the characterization factor: the dose-response and severity factor (which together are basis 
of the effect factor), and the intake fraction. These three issues are:
1. Van Zelm et al.’s use of local European background mortality was not necessarily 
consistent with the U.S.-population background mortality from which the dose-
responses were derived.
2. A new effect factor (the product of dose-response and severity factor) can be 
calculated using alternative methods of calculating the severity factor (DALY/
death) that draw on the revised 2010 Global Burden of Disease Study (GBD) 
disease-specific DALY.
3. A set of new intake fractions, accounting for both the emissions source height and 
the “archetypal” emissions environment (urban, rural, or remote locations) and 
covering both primary and secondary particulates, calculated by Humbert et al. 
(2011), are now available.
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This paper addresses these issues by developing updated components to the characterization 
factor, calculating a new characterization factor for PM, and assessing its performance, 
through the following five objectives:
1. Determine new PM2.5 dose-response factors (deaths/kg PM2.5 inhaled) by using 
age- and cause-of-death specific results from Reanalysis of the American Cancer 
Society Study of Particulate Air Pollution and Mortality (the ACS Study, (Pope et 
al. 2002)) and PM2.5 concentrations in 63 U.S. Standard Metropolitan Statistical 
Areas (SMSAs). Calculate the dose-response factors in terms of PM2.5 (as opposed 
to PM10), which is the fraction of PM10 with sufficient evidence to support a likely 
causal relationship with health endpoints (Humbert et al. 2011; U.S. Environmental 
Protection Agency 2010).
2. Calculate new severity factors based on 2010 GBD disease-specific DALY and 
total effect factors for PM-related effects, in term of years of life lost (YLL) and 
DALY.
3. Combine the new dose-response and severity factors with the new intake fractions 
(Humbert et al. 2011) to calculate and recommend PM2.5 characterization factors 
that can be used for LCIA in different world regions.
4. Calculate the overall burden of disease attributable to PM in the U.S. based on a) 
ambient levels of PM2.5 and b) emissions of primary and secondary PM2.5 using 
the revised intake fraction, and compare the results from these two methods to 
assess the new characterization factors.
5. Compare our estimate of the U.S. burden of disease associated with PM to other 
estimates in the literature.
2. MATERIALS AND METHODS
Figure 1 provides an outline of our methods for estimating a characterization factor as well 
as the burden of disease for PM2.5 both within and outside the LCIA framework. We first 
used the intake fractions (kginhaled/kgemitted) estimated by Humbert et al. (2011) to assess 
exposures. Building on those fractions, we then estimated dose-response factors (cases/
kginhaled) and severity factors (DALY/case), and multiplied these two quantities to estimate 
an age-adjusted effect factor (DALY/kginhaled). Next, we multiplied the effect factor with 
intake fractions to estimate the characterization factor (DALY/kgemitted). Finally, we 
estimated a U.S. PM2.5 burden of disease based on these characterization factors and 
compared it to a PM2.5 disease burden based on directly monitored PM2.5 levels. The details 
of this process are provided below, and further details and derivations of the methods are 
provided in Appendix A.
2.1 Concentration-and dose-response factors
We calculated concentration-response factors (CRF, PM2.5-associated annual mortality rate 
per μg/m3 PM2.5 inhaled) for mortality, for each age group and cause of death 
(cardiopulmonary disease, lung cancer and all causes), as the population-weighted average 
of the CRF in each metropolitan area i
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where MRtotal,i is the annual mortality rate for metropolitan area i in deaths/person/year, 
POPi is the population size of metropolitan area i in persons, Ci is the PM2.5 concentration 
in area i and RR is the increased risk of mortality per unit increase in Ci. We obtained RRs 
for four age groups (30 years and older, 30-59, 60-69, and 70 and older) (Appendix B Table 
4) from the ACS Study (Pope et al. 2002). The ACS Study estimated the increased risk of 
death among adults 30 years of age and older due to all causes, cardiopulmonary diseases 
and lung cancer associated with levels of ambient PM2.5 in cities across the U.S. We based 
our final characterization factor on the cardiopulmonary and lung cancer mortality results, 
rather than the all-cause results, because of their plausibility of association with PM2.5, 
although we considered estimates using the all-causes RRs as well.
RRs are not very “portable” or generalizable from one population to another (Steenland and 
Armstrong 2006). Therefore, to provide the best estimate for our CRF, we used age-specific 
mortality rates from a population similar to that of the ACS study--a white, U.S. population 
from the same time period as the ACS study (Intercensal Population Estimates by Age, Sex, 
and Race: 1980-1989 2009; National Center for Health Statistics 2010). Average PM2.5 
concentrations for 63 SMSAs from 1979-1983 were obtained from Appendix D of Part II of 
the ACS Study (Krewski et al. 2000). It is important to note that several other cohort studies 
relate mortality to PM2.5 (Hoek et al. 2013). We chose to use the ACS study because of its 
large sample size, its broad distribution of cities across the U.S., rigorous control for 
multiple confounders and the availability of mortality rate and exposure data consistent with 
the study. Furthermore, in a meta-analysis of long-term air pollution exposure and 
cardiopulmonary mortality studies, the weighted mean of the RRs in the meta-analyses were 
similar to those of the individual ACS study RRs (Hoek et al. 2013), further validating our 
choice to use the ACS study RRs rather than RRs pooled across studies.
The dose-response factor (PM2.5-associated deaths per kg PM2.5 inhaled) was then 
calculated as the CRF divided by the IH, where IH was the annual inhalation rate of an 
average individual, which was estimated as 4,745 m3/person (U.S. Environmental Protection 
Agency 1997).
2.2 Severity factors and effect factors
Severity factors relate the cases of death attributed to PM, determined by the above-
described dose-response, to the corresponding number of disability-adjusted life years 
(DALY) (Murray and Lopez 1996) and are expressed in terms of DALY/death. The severity 
factors for cardiopulmonary and lung cancer deaths were calculated from the Global Burden 
of Disease Study 2010, for the high-income North America region (Global Burden of 
Disease Collaborators 2013). We determined DALY/death and YLL/death based on the 
simplifying assumption that, e.g., the ratio of DALY/death for all causes (not just PM2.5) of 
cardiopulmonary mortality is equivalent to the ratio of DALY/death for PM2.5-associated 
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cardiopulmonary mortality (Steenland and Armstrong 2006). For the all-cause severity 
factors, we used cardiopulmonary and lung cancer outcomes, assuming that these causes 
would more accurately reflect the severity of PM-associated disease.
Effect factors were then calculated within each age group as the product of the dose-
response factors and the severity factors. The overall effect factor for 30 years and older was 
calculated as the population-weighted mean of the age specific factors (assuming an effect 
factor of 0 for ages 0-29) using either the U.S. population as weights or the WHO World 
Standard Population for 2000-2025 (http://www.who.int/whosis/indicators/compendium/
2008/1mst/en/index.html). As a sensitivity analysis, these effect factors were compared to 
the effect factors we calculated using available dose-response relationships in the literature 
for specific morbidity outcomes associated with PM, although we were skeptical of the 
breadth and quality of these available dose-response relationships (see Appendix C for 
further discussion).
2.3 Characterization factors – impact per kg emitted
Intake fractions from Table 3 in Humbert et al. (2011) were combined with the newly 
calculated dose-response factor and severity factors (described in sections 2.1 and 2.2) to 
calculate updated characterization factors for primary and secondary PM2.5. The uncertainty 
around our characterization factors was then estimated as follows. Assuming uncertainties in 
intake fraction, dose-response, and severity factors were uncorrelated and assuming 
characterization factors have a log-normal distribution, the square of the geometric standard 
deviation (GSD2) of the characterization factor was estimated as
(2)
Our 95% confidence intervals around our point estimates were then (estimate/GSD2, 
estimate · GSD2), and our 90% confidence intervals were (estimate/GSD1.6, estimate · 
GSD1.6).
2.4 Burden of disease—impact per year
2.4.1 Estimate using ambient concentrations—The county-specific PM2.5 
concentrations were obtained from the EPA’s BenMAP 3.0 (Abt Associates Inc. 2008), and 
average annual population data for each county and age group (years 2005-2009) were 
obtained from the American Community Survey U.S. Census Bureau 2010).
We calculated the burden of disease (DALY/year) in 2005 as the product of the 
concentration response factor (CRF, equation 1), the severity factor (SF), the population 
(POP) and the PM2.5 concentration (C), summed over each combination of cause of death 
(d), county (i) and age group (a).
(3)
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This method differs from previous burden-of-disease estimates in that a constant baseline 
mortality rate is assumed in each county (for each age group and cause of death). An 
absolute increase in disease burden is then calculated using a concentration-response factor 
and population counts rather than multiplying the total mortality rate in that county by the 
attributable fraction. We therefore avoid misestimating the burden of disease as can occur 
when an attributable fraction is multiplied by a mortality rate that may be substantially 
elevated or diminished for reasons other than ambient particulate exposure, e.g., smoking. 
For comparison, we also estimated the burden of disease using an attributable fraction 
instead of a CRF:
(4)
where MR was the annual mortality rate based on 1980-1988 mortality and POP was the 
annual population from 2005-2009.
2.4.2 Estimate using emissions inventory—We obtained county-specific emissions 
of primary PM2.5, SO2, NOx, and NH3 from the EPA’s 2005 National Emissions Inventory 
(U.S. Environmental Protection Agency 2005). U.S.-specific characterization factors were 
then calculated using intake fractions from Table S1 and equations S11-S16 in Humbert et 
al. (2011).
In LCIA, where ambient pollutant concentrations resulting from a specific product or 
process are usually not known, the impact or total burden can be calculated by multiplying 
the characterization factor and the emission mass due to a functional unit of this product 
over its life cycle. Likewise, using characterization factors, the overall national burden of 
disease from PM due to all products and processes can be calculated by multiplying the 
emissions by the effect factor and the intake fraction (the characterization factor: iF · EF), 
and summing over each combination of county (i), pollutant (j) and stack height (h).
(5)
where Memitted ijs is the yearly mass of pollutant j emitted from stack height h in county i 
(kgemitted y-1). For this calculation, an effect factor weighted by the U.S. population in each 
age group was generated for each county.
The emission-based burden of disease of equation 5 can be directly compared to the 
concentration-based burden of disease of equation 3 to test its validity. Because we used 
identical effect factors (DALY per kg PM2.5 inhaled) for each county, this method 
essentially compares the intake (kg PM2.5 inhaled) calculated using emissions to the intake 
calculated using ambient concentrations.
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3. 1 PM2.5 dose-response factor
The population-weighted average of PM2.5 concentration across the 63 SMSAs was 21.2 
ug/m3 (Table 1). Age-adjusted cardiopulmonary and lung cancer mortality rates ranged 
widely across SMSAs, from 580 to 870 deaths per 100,000 population. The mean age-
adjusted attributable fraction for PM2.5 ranged between 6.6% and 19% for cardiopulmonary 
causes of mortality, with an average of 12% among individuals aged 30 years and older. The 
attributable fraction was as high as 23% for lung cancer mortality in the 60-69 age group 
(Appendix B Table 5), with an average of 8.6% for 30 years and older (Table 1).
We estimated a combined dose-response factor of 4.2 deaths per kg PM2.5 inhaled for 
cardiopulmonary and lung cancer mortality and an equivalent concentration-response factor 
of 2.0 deaths per 100,000 population per μg/m3 PM2.5 inhaled (Table 1). The concentration-
response factor may be used when ambient concentrations are known.
3. 2 PM2.5 Severity factors and total effect factors
For cardiopulmonary and lung cancer, the severity factor of 19 DALY is dominated by YLL 
as opposed to YLDs which account for only 4 additional DALY (Table 1).
Our default factor for LCIA of 78 DALY per kg PM2.5 inhaled (Table 1), based on the total 
WHO World Standard Population, is lower than our U.S.-specific effect factor (110 DALY 
per kg PM2.5 inhaled) due to the fact that the WHO standard population is younger than the 
U.S. population. Our WHO-population effect factor based on the RR for all-cause mortality 
is higher (110 DALY per kg PM2.5 inhaled).
3.3 Combining effect and intake factors to determine characterization factors
Table 2 combines the effect factor of 78 DALY per kg PM2.5 inhaled with the set of default 
intake fractions provided for various conditions by Humbert et al. (2011). Most life cycle 
inventories and LCIAs are still performed without knowledge of the source type and 
location of PM emissions. In these cases, a default, emission-weighted average 
characterization factor of 1.2E-03 DALY/kg primary PM2.5 emitted would be used (grey 
cells in Table 3). When the type of emission source and its location are known for 
foreground processes (i.e., the processes directly evaluated in the LCIA), the 
characterization factor for the respective source and location should be used.
The uncertainty around our characterization factor estimates was great. The GSD2 of the 
emission-weighted intake fraction has been evaluated to be 5.3 (Humbert et al. 2011). Given 
that the majority of the uncertainty in the dose response factor is due to the (RR – 1) term in 
the numerator, the GSD2 of the dose response factor was roughly estimated as 2.2 based on 
RR point estimates as low as 1.03 and as high as 1.13 per 10 μg/m3 increase in PM2.5 for all 
causes of mortality in sensitivity analyses of the ACS Study conducted by Krewski et al. 
(2009). The GSD2 of the severity factor was qualitatively estimated as 1.4 given de 
Hollander et al.’s earlier estimate of 10 DALY per death (de Hollander et al. 1999) 
compared to our estimate of 19 DALY per death. According to equation 2, the world 
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primary PM2.5 emissions-weighted characterization factor of 1.2E-03 therefore has a GSD2 
of 6.5 and a 95% CI of (1.8E-04, 7.6E-3).
3.4 Contribution of PM2.5 to annual United States burden of disease
3.4.1 Human health damage based on annual United States ambient PM 
concentrations
Comparison with Global Burden of Disease U.S. Estimates and EPA Estimates: We 
estimated a PM burden of disease for the entire U.S. in 2005 of 130,000 deaths and 2 million 
DALY, without considering any minimum threshold concentration, and we compared our 
burden of disease estimates to those of the GBD and the U.S. EPA for two different 
minimum thresholds of PM2.5 (Table 3). We used methods similar to those used by the U.S. 
EPA in estimating the U.S. burden of disease—RRs from the ACS Study and county-level 
air quality inputs. When using attributable fractions (as the EPA did) in conjunction with 
background mortality from an earlier time period (1982-1988) we estimated a higher burden 
of disease of 150,000 deaths compared to the 110,000 annual deaths estimated by the EPA. 
Estimates based on cardiopulmonary and lung cancer mortality were almost identical to 
estimates based on all-cause mortality. When we used our age-specific concentration-
response functions instead of attributable fractions, our estimate dropped to 130,000 deaths 
annually.
Above a background concentration of 4 μg/m3, our estimates of 52,000 deaths and 960,000 
DALY, adjusted to the World Health Organization Standard Population, were much lower 
than the Global Burden of Disease U.S. estimates of 103,000 deaths and 1,800,000 DALY.
Comparison of our estimate of PM2.5 effects on life expectancy to Pope et al.(2009): 
Based on a regression of national mortality statistics and PM concentrations for 51 U.S. 
metropolitan areas, Pope et al. (2009) have estimated the increase in life expectancy for each 
10 μg/m3 decrease in PM2.5 to be 0.61 (95% CI: 0.22 – 1.0) years. For adults over 30 years 
of age, we estimated 0.00037 deaths (all-cause) per person per 10 μg/m3 inhaled per year 
(concentration-response factor adjusted to the U.S. 2000 population) and a severity factor of 
17 YLL per death (Table 1). Multiplying these two factors by a healthy life expectancy of an 
additional 52 years after age 30 per person (Mathers et al. 2006b), we estimate an increase in 
life expectancy of 0.33 years per person for each 10 μg/m3 decrease in PM2.5. Our result 
falls within Pope et al.’s 95% confidence interval.
3.4.2 Human health damage based on annual United States primary and 
secondary pollutant emissions and characterization factors—Using 2005 U.S. 
emissions and urban and rural characterization factors, we estimated the annual intake of 
PM2.5 as 38,000 kg PM2.5, which was 2.2 times higher than the estimate based on actual 
ambient concentrations. Figure 2 plots the logarithm of the PM2.5 intake estimated using 
ambient concentrations vs. the intake estimated using the emissions inventories and 
characterization factors in order to examine the concordance between the intake and burden 
of disease calculations by county. We would not expect the two values to match for each 
county because the “emissions” intake is based on the intake due to the county emissions 
without regard to the location of the affected population (not just the population within that 
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county). The S-shaped scatterplot reflects this, where the emissions-based intake is lower 
than the ambient concentration-based intake in counties with low emissions and higher than 
the ambient concentration based intake in counties with high emissions. Nevertheless, the 
two estimates are within a factor of 10 for 91% of the counties, with closer agreement 
among the counties with a population density less than the median of 15 persons per km2 
(for the log-transformed values, t=-24, p < 0.0001).
4. DISCUSSION
We present here an updated methodology to characterize the disease burden associated with 
particulate air pollution exposure for application in LCIA that addresses several issues in 
previous work. The newly calculated characterization factors are based on age- and cause-
of-death specific data and are based on the US-population background mortality from which 
the PM2.5 dose-responses were derived as well as the revised disease-specific severity 
factors from the 2010 GBD. By combining our updated effect factors with the new intake 
fractions of Humbert et al. (2011), we calculated revised impact per kg primary and 
secondary particulate emitted for a default region as well as for specific world regions. 
Below, we compare our dose-response factor, effect factor, severity factor and 
characterization factor calculations as well as our burden of disease calculations to previous 
calculations.
Assuming that PM2.5 is approximately 1.67 times more toxic than PM10 (European 
Commission 2005), our dose-response factor is 27% lower than the PM dose-response factor 
calculated by Van Zelm et al. (2008) who estimated a dose-response factor of 5.76 deaths 
per kg PM10 inhaled (Appendix C Table 8). Consequently, in term of YLL, the estimate of 
64 YLL per kg PM2.5 inhaled we obtained is also 33% lower than the 96 YLL due to PM2.5, 
obtained by Van Zelm et al. (2008). However, our estimate of morbidity due to PM2.5 of 14 
YLDs per kg PM2.5 inhaled (Table 1) is much higher than that estimated by Van Zelm et al. 
of 0.055 YLDs per kg PM2.5 inhaled (Appendix C Table 8). Therefore, our resulting effect 
factor of 78 DALY per kg PM2.5 inhaled is only 19% lower than the Van Zelm et al. effect 
factor of 96 DALY per kg PM2.5 inhaled (after converting from PM10 to PM2.5, Appendix C 
Table 8).
Our severity factors are higher than a previous estimate by De Hollander et al., who 
calculated the environmental burden of disease in the Netherlands and estimated weight 
factors for various causes of morbidity attributed to PM (de Hollander et al. 1999). De 
Hollander et al. estimated 10.1 YLL per death. The YLL severity factor in the present study 
is higher (15 YLL/death). The additional 5 YLDs/death in the present DALY severity factor 
represent morbidity due to cardiopulmonary diseases including chronic bronchitis, which 
accounts for 37% of the cardiopulmonary YLDs in the high income North America region 
(Global Burden of Disease Collaborators 2013). Nevertheless, our severity factor remains 
dominated by death, yielding an overall factor of 19 DALY per death due to PM2.5.
For primary PM2.5, our characterization factor of 1.2E-03 (Table 2) is 2.7 times higher than 
Van Zelm’s factor of 4.3E-4, as converted from the PM10 estimates accounting for the 
respective proportion of PM10 emitted as PM2.5 for the primary and secondary PM 
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(Humbert et al. 2011). This results from higher intake fractions (3.1 times higher) multiplied 
by lower effect factors (27% lower as discussed above), obtained using U.S. mortality rate 
inputs, age-group specific RRs and chronic morbidity due to PM2.5. Our characterization 
factors for secondary PM2.5 due to SO2 and NH3 of 6.9E-5 and 1.3E-4 are virtually the same 
as Van Zelm’s factors of 6.9E-5 and 1.4E-4, while our characterization factor for secondary 
PM2.5 of 1.4E-5 due to NOx is lower than Van Zelm’s factor of 6.2E-5 due to our use of a 
lower intake fraction.
The factors suggested in this paper update the factors provided by Humbert (2009) which 
are currently recommended by the European Commission in its Production and Organization 
Environmental Footprint methodologies (Wolf et al. 2012). The factors suggested in this 
paper are about a third lower than the factors provided by Humbert (2009) for primary 
PM2.5 and secondary PM from SO2, and are about the same for secondary PM from NOx 
and NH3. The correspondence between our revised characterization factors and previous 
ones suggests that conclusions used in previous LCIA using those methods would still be 
largely valid.
Our estimate based on ambient concentrations is 2.2 times lower than our estimate based on 
PM2.5 emissions inventories and characterization factors in the U.S., and this difference is 
due to the additional assumptions about intake required when using emissions inventories 
and characterization factors instead of known ambient concentrations. In county-by-county 
comparisons, the two intake estimates differed by less than a factor of 10 for 91% of the 
counties. The intake fraction is heavily dependent on assumptions about the density of the 
population near the emissions source, so it was not surprising that the uncertainty in the 
intake fraction is larger for counties with higher population densities. The general 
concordance of the emissions and characterization factor-derived results with the ambient 
concentration results supports the use of these characterization factors for LCIA.
Our U.S. burden of disease estimates based on ambient levels of PM2.5 fall in the range the 
estimates derived by the U.S. EPA in 2010. When using a CRF, which provides an estimate 
of risk on an absolute scale, as opposed to the direct use of an attributable fraction for each 
county which estimates risk relative to the baseline mortality in that county, our results did 
not change substantially. This is not surprising given that we made this comparison using a 
population similar to that used to derive the RRs. Pope et al.’s (2009) life expectancy 
estimate was also similar to ours, which again, is not surprising considering that a similar 
study population was used. Our results reinforce that U.S. health-based air quality standards 
that are based on previous burden of disease and life expectancy estimates are robust to the 
methodologic differences we addressed here. The advantage of using a CRF is that it 
produces results for other countries and regions that are less dependent on background 
mortality, and this method is more relevant to instances when epidemiologic evidence from 
one population is applied to another, as in LCIA.
Our burden of disease estimate falls below the GBD estimate, likely due to the higher RRs 
used in the GBD, which were modeled from multiple cohort studies of ambient air pollution 
as well as secondhand tobacco smoke, indoor solid cooking fuel and active smoking (US 
Burden of Disease Collaborators 2013). The RRs in the GBD modeling were allowed to vary 
Gronlund et al. Page 10













by exposure concentration (Burnett et al. 2014), although any possible biological 
mechanisms explaining the resulting non-linear dose-response relationships were not 
proposed. For the purposes of LCIA a linear, no-lower-threshold dose response curve is 
often assumed. Although the health effects of PM2.5 may actually be attenuated in countries 
with higher background PM2.5 levels, (Ostro 2004) a linearity assumption may still be 
appropriate in LCIA applications in which one would not want an inter-regional comparison 
of the additional adverse health effects due to a process to be influenced by the background 
PM2.5 levels in those regions. On the other hand, in indoor settings, our characterization 
factor would possibly overestimate PM-attributable health effects considering much higher 
concentrations of PM are often observed indoors, and more research is needed to quantify 
the health effects of indoor PM (Smith and Peel 2010). Even solely among studies of 
mortality and ambient air pollution, considerable heterogeneity in the effect estimates exists 
(Hoek et al. 2013), and some of this heterogeneity may be due to differences in baseline 
mortality risk from study to study. Additional research needs in refining estimates of PM-
related health effects as well as limitations of the present study are listed below.
PM regulations and epidemiology studies typically focus on PM mass. If and when PM 
number, surface area and composition are shown to be important and robustly quantifiable 
in dose-response relationships, it will be necessary to reevaluate results presented here.
The ACS Study did not control for other air pollutants or noise pollution. There is a demand 
for improved health effects modeling of multiple, correlated air pollutants simultaneously, 
and techniques for addressing this challenge are being developed (Dominici et al. 2010). In 
the meantime, the effects of PM reported in this paper should be applied cautiously 
considering that some of the effect attributed to PM may be due to other air pollutants. In 
LCIA, because PM health effects are often much higher than the effects of other air 
pollutants, the PM health effects serve as a proxy for the environmental health effects of air 
pollutants generated by that product or process.
Our simplified severity factor calculation attempts to avoid the gaps in knowledge regarding 
PM-associated morbidity. However, Appendix C Table 8 suggests that our severity factor 
could still be underestimating PM-associated morbidity due to chronic bronchitis. Also, the 
effect factor recommended here uses only dose-response information based on adults. The 
influence of PM inhalation on low birth weight (Bell et al. 2008) and asthma among children 
and expressing this influence in terms of DALY also deserves further attention.
We have updated the PM characterization factor so that future LCIAs may have more 
precise comparisons of the health burden of PM from various products or processes. 
However, our uncertainty intervals are still relatively wide, and advances in modeling the 
intake fraction are needed. For both LCIA and estimates of the burden of disease due to PM, 
a better understanding of the mechanisms behind a potentially non-linear dose-response 
relationship and sources of heterogeneity in effect estimates is needed. Nevertheless, the 
PM2.5 attributable fractions for cardiopulmonary disease as well as lung cancer were high 
(9-12% on average) indicating that PM2.5 represents an important exposure contributing to 
mortality in the U.S. and is fundamental to our understanding of the health impacts of PM 
throughout a product or process’s life cycle.
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Appendix A: Additional Materials and Methods
Concentration- and dose-response factors
Data
The RRs in the ACS Study (Pope et al. 2002) accounted for confounding by several 
individual risk factors (age, sex, race, smoking, education, marital status, body mass, alcohol 
consumption, occupational exposure, and diet) and spatial autocorrelation. The ACS Study 
evaluated differences in mortality associated with chronic (multi-year) PM2.5 exposure, but 
some of the short-term effects of PM2.5 are likely captured in this study type. Although time 
series studies of mortality and morbidity associated with only short-term exposure to PM2.5 
have been conducted, characterization factors based on these have been estimated to be 2-4 
orders of magnitude lower than the characterization factor for mortality due to chronic 
exposure in past calculations (van Zelm et al. 2008). Therefore, short-term effects are not 
addressed separately here.
To elaborate on the point that RRs are not very “portable” or generalizable from one 
population to another (Steenland and Armstrong 2006), RRs estimate health effects relative 
to the baseline levels of that health effect. For example, a country may have a higher rate of 
mortality than the U.S. among individuals aged 55-59, due to causes other than outdoor 
pollutants, such as tobacco smoke. Therefore, the fraction of deaths attributable to PM 
would be overestimated in that country if a U.S.-based study were used for the calculation. 
Thus, in estimating absolute increases in a particular health effect per unit of pollutant, it is 
better to be consistent between the study population used to derive the RR and the 
corresponding health effect data. Because the RRs were derived from the ACS Study cohort, 
to calculate a PM2.5 attributable fraction, we obtained mortality and population data for U.S. 
SMSAs by age group. We used this U.S.-based data because the distribution of population 
factors that may modify the association between PM2.5 and mortality, such as tobacco 
smoking, would be more likely comparable with those in the ACS study population than 
data from another country. Also, because the ACS Study population was 94% white, dose-
response factors were calculated using mortality rates among whites only to ensure 
consistency.
U.S. mortality data were obtained from the U.S. Centers for Disease Control and 
Prevention’s National Center for Health Statistics (National Center for Health Statistics 
2010). After 1988, one-year-age-specific mortality data was made available only for 
counties and cities with populations greater than 100,000 persons (Data Release Policy, 
http://www.cdc.gov/nchs/nvss/dvs_data_release.htm), so counts of deaths by five-year age 
group and cause of death for each SMSA were calculated for the years 1982-1988, within 
the follow-up period for the ACS Study (1982-1998). The ACS Study only enrolled 
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individuals aged 30 years and older, so only mortality data for decedents 30 years and older 
were considered. Annual mortality rates for each cause of death were calculated by dividing 
the deaths by annual population estimates for each age group, which were obtained from the 
U.S. Census (Intercensal Population Estimates by Age, Sex, and Race: 1980-1989 2009). 
The seven years were then averaged by five-year age group, cause of death and SMSA.
Calculation
The concentration-response factors (CRF, PM2.5-associated annual mortality rate per μg/m3 
PM2.5 inhaled) for mortality, for each cause of death (cardiopulmonary disease, lung cancer 
and all causes) and age group, were defined as the population-weighted increase in mortality 
rate attributed to PM2.5 in the U.S. SMSAs divided by the average PM2.5 concentration:
(6)
where MRPM2.5,i is the PM2.5-associated annual mortality rate for metropolitan area i in 
deaths/person/year, and Ci is the PM2.5 concentration (in μg/m3 = 10-9 kg/m3) in area i.
From Cox proportional hazards models (and other log-linear models commonly used in 
epidemiology studies), the RR (unitless) for each unit increase in PM2.5 concentration (C in 
μg/m3) is equivalent to eβ, where β is the increase in ln (deaths) per 1 μg/m3 increase in 
PM2.5. Considering that in the range of applicable PM2.5 concentrations and RRs in the U.S., 
the association between mortality and PM is approximately linear, the attributable fraction 
for metropolitan area i, or the proportion of total cases attributable to PM2.5 in that 
metropolitan area, is
(7)
The concentration-response factor for metropolitan area i therefore becomes
(8)
PM2.5 concentration and mortality rate vary by location within the U.S., but the RRs 
presented in the ACS Study were not specific to any one metropolitan area. Therefore, the 
recommended concentration-response factor (for each cause of death and age group) was 
calculated as a population-weighted average of the concentration-response factors of 
individual metropolitan areas. This can also be represented as the increase in risk multiplied 
by a population-weighted non-PM mortality rate (last term of equation 9):
(9)
where POPi is the population size of metropolitan area i in persons.
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Severity factors and effect factors
The human health burden of disease due to the emission of an atmospheric pollutant can be 
expressed using disability-adjusted life years (DALY) (Murray and Lopez 1996). DALY are 
the sum of years of life lost (YLL) and years of life lost due to disability (YLDs) for a 
disease. YLDs are the product of the incidence, duration and weight factor (on a scale of 0 
(perfect health) to 1 (death)) for that disease (Murray and Lopez 1996). Severity factors 
relate the cases of death attributed to PM, determined by the above-described dose-response, 
to the corresponding number of DALY. Severity factors are expressed in terms of DALY/
death, where “death” in the denominator refers to the PM-attributed cases of 
cardiopulmonary or lung cancer mortality calculated using the DRFs.
We used DALY and YLL which do not include age weights or 3% discounting; these have 
been taken as the standard for LCIA (Crettaz et al. 2002; Hofstetter 1998; Pennington et al. 
2002; van Zelm et al. 2008). Users interested in a value-of-statistical-life quantity (VSL) 
may convert the PM2.5-associated mortality rate to a VSL.
Effect factors for secondary PM2.5 were assumed to be equivalent to effect factors from 
primary PM2.5 since the effect factor was derived from monitors capturing a mixture of 
primary and secondary PM2.5.
Characterization factors – impact per kg emitted
The human health impact per kg of a given atmospheric emission, called the characterization 
factor (CF, DALY kgemitted-1), is the product of four parameters:
(10)
The fate factor (FF, kgair per [kgemitted y-1]) relates the emission rate (kgemitted y-1) to the 
mass in the exposure medium (kgair); the exposure factor determines the change in intake 
rate per change in mass in the environment (XF, [kginhaled y-1] per kgair); and the dose-
response factor indicates the change in morbidity or mortality attributable to a change in 
intake (DRF, cases per kginhaled). The emitted pollutant can be a single chemical or a group 
of chemicals, and it can be a primary pollutant or a contributor to a secondary pollutant 
(Rosenbaum et al. 2007). The product of SF and DRF is the effect factor (EF, DALY 
kginhaled-1) and the product of XF and FF is the intake fraction (iF, kginhaled per kgemitted). 
The intake fraction for primary pollutants indicates the fraction of the emission taken in 
(inhaled) by the overall population (Bennett et al. 2002). The intake fraction for secondary 
pollutants is the inhaled mass of the pollutant attributable to a specific precursor per mass 
emission of the precursor.
Since coarse (between 2.5 and 10 microns in aerodynamic diameter, PM10-2.5) particles are 
likely removed faster from the atmosphere than fine particles (iF (PM10-2.5) < iF(PM2.5 (Lai 
et al. 2000; Liu and Nazaroff 2003)) and the effect factor of coarse particles is lower (EF 
(PM10-2.5) ≪ EF (PM2.5) (Brunekreef and Forsberg 2005; Cooke et al. 2007; Dockery et al. 
1993; European Commission 2005; Hofstetter 1998; U.S. Environmental Protection Agency 
2010)), the overall characterization factor is therefore dominated by PM2.5:
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where fPM2.5 is the fraction of PM10 which is emitted as PM2.5.
Burden of disease—impact per year
Estimate using ambient concentrations—PM2.5 concentrations for each county in the 
nation were estimated using Voronoi neighborhood averaging of 2005 ambient monitor data 
from the EPA’s BenMAP 3.0 software which estimates health benefits from reductions in 
air pollutants (Abt Associates Inc. 2008).
Estimate using emissions inventory—Stack-height specific characterization factors 
were assigned to each emissions source according to Table S2 in Humbert et al. (2011). 
Emissions with uncategorized stack heights were assigned to the low stack height category. 
The characterization factors were weighted according to the proportion of the population 
that was considered urban vs. rural in the U.S. 2000 Census. The characterization factors for 
remote sources were applied in counties with population densities less than 10 persons/km2.
Appendix B: Age- or Location-Specific Data and Results
Table 4
Mortality risk ratios (RRs) associated with PM2.5 exposure derived from the ACS Study 
(Pope et al. 2002) (Figure 4) by cause of death and age group.
Age Group (years) RR per 10 μg/m3 PM2.5 (95% Confidence Interval)
All-Cause Mortality
30 and older 1.04 (1.01, 1.08)
30-59 1.04 (1.00, 1.09)
60-69 1.02 (0.97, 1.06)
70 and older 1.05 (1.00, 1.09)
Cardiopulmonary Mortality (ICD-9 codes 401-440 and 460-519)
30 and older 1.06 (1.02, 1.10)
30-59 1.05 (0.98, 1.14)
60-69 1.02 (0.97, 1.07)
70 and older 1.08 (1.03, 1.15)
Lung Cancer Mortality (ICD-9 codes 162)
30 and older 1.08 (1.01, 1.16)
30-59 1.04 (0.95, 1.14)
60-69 1.14 (1.03, 1.27)
70 and older 0.98 (0.84, 1.16)
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Population-weighted means for annual total mortality rates, non-PM mortality rates and 
PM2.5 attributable mortality rates per 100,000 population and attributable fractions by each 
























Total mortality rates, 1982-1988
Cardiopulmonary 13 28 59 120 230 390 680 1,100 1,900 3,100 8,100
Lung Cancer 0.98 3.6 12 31 65 120 180 240 290 300 250
All causes 120 160 230 360 590 950 1,500 2,300 3,500 5,200 12,000
Attributable fractions
Cardiopulmonary 0.094 0.094 0.094 0.095 0.095 0.096 0.035 0.035 0.15 0.15 0.15
Lung Cancer 0.075 0.075 0.075 0.076 0.076 0.076 0.23 0.23 -0.034 -0.034 -0.034
All causes 0.077 0.077 0.077 0.077 0.078 0.078 0.041 0.041 0.095 0.095 0.095
Non-PM mortality rates
Cardiopulmonary 13 25 53 110 200 360 660 1,100 1,600 2,600 6,900
Lung Cancer 0.91 3.3 11 28 60 110 140 180 300 310 260
All causes 110 150 210 330 540 880 1,400 2,200 3,100 4,700 10,000
PM2.5-attributable mortality rates
Cardiopulmonary 1.3 2.7 5.6 11 22 38 24 39 290 470 1,200
Lung Cancer 0.073 0.27 0.89 2.3 5.0 9.0 41 54 -9.8 -10 -8.3
All causes 9.6 12 17 28 46 75 61 93 330 500 1,100
Table 6
Population-weighted means for dose-response and concentration-response factors and final 
























Concentration-response factor (mortality rate (per 100,000 population) per μg/m3 PM2.5)a
Cardiopulmonary .063 0.13 0.27 0.54 1.0 1.8 1.1 1.8 14 22 58
Lung Cancer 0.0040 0.013 0.043 0.11 0.24 0.42 1.9 2.6 -0.46 -0.48 -0.39
All causes 0.46 0.59 0.83 1.3 2.2 3.5 2.9 4.3 16 23 52
Dose-response factor (deaths per kg PM2.5 inhaled)a
Cardiopulmonary 0.13 0.27 0.56 1.1 2.1 3.8 2.4 3.9 29 47 120
Lung Cancer 0.0070 0.027 0.090 0.23 0.50 0.89 4.0 5.4 -0.97 -1.0 -0.83
All causes 0.96 1.2 1.7 2.8 4.6 7.4 6.1 9.2 33 49 110
Severity Factors
DALY/death
Cardiopulmonary 120 92 68 55 47 40 33 27 21 16 6.9
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Lung Cancer 54 49 44 40 35 30 26 21 17 13 6.2
All causesc 120 88 65 52 44 37 31 25 20 15 6.9
YLL/death
Cardiopulmonary 54 49 44 39 35 30 25 21 17 13 5.8
Lung Cancer 54 49 44 39 35 30 25 21 17 13 6.0
All causesc 54 49 44 39 35 30 25 21 17 13 5.8
Effect Factors
DALY/death
Cardiopulmonary 16 24 38 63 100 150 77 100 600 750 850
Lung Cancer 0.40 1.4 4.0 9.3 17 27 100 120 -17 -13 -5.1
All causes 120 110 110 150 200 280 190 230 660 760 760
YLL/death
Cardiopulmonary 7.1 13 25 44 74 110 60 82 480 600 720
Lung Cancer 0.40 1.3 4.0 9.2 17 27 100 110 -16 -13 -4.9
All causes 52 61 77 110 160 220 150 190 550 630 640
a
N = 63 U.S. Standard Metropolitan Statistical Areas.
b
Based on the Global Burden of Disease 2010 Estimates of Deaths, DALY and YLL for the High-Income North America 
region.
c
The all-causes severity factors are actually the cardiopulmonary+lung cancer severity factors as these are more likely to 
reflect the severity of PM-associated disease.
YLD = DALY – YLL
Table 7
Emission-weighted average world region-specific characterization factors for primary 
PM2.5.
Urban Rural Remote Population-weighted average
World 2.0E-03 2.0E-04 7.8E-06 1.2E-03
Generic continent 1.2E-03 7.2E-05 7.8E-06 6.6E-04
US+Latin America 2.3E-03 5.9E-05 7.8E-06 9.4E-04
Europe 1.4E-03 1.6E-04 7.8E-06 7.8E-04
Africa+Middle East 2.0E-03 8.6E-05 7.8E-06 6.2E-04
Central Asia 1.6E-03 1.0E-04 7.8E-06 5.1E-04
South East Asia 2.3E-03 3.6E-04 7.8E-06 1.6E-03
Arctic 7.3E-04 3.3E-05 7.8E-06 1.4E-04
Oceania 9.4E-04 2.3E-05 7.8E-06 3.8E-04
Antarctica 0.0E+00 0.0E+00 7.8E-06 7.8E-06
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Appendix C: Alternate Severity and Effect Factors
Estimates of disability due to PM in Appendix C Table 8 do not make the assumption that 
morbidity due to PM2.5 is equivalent to morbidity due to other causes of that disease. Most 
of these estimates are small compared to the estimate of chronic mortality with the exception 
of disability due to chronic bronchitis. Künzli et al. (2000) estimated a high burden of 
chronic bronchitis due to PM using both incidence rates and risk ratios from the Seventh-
Day Adventist Cohort Study (Abbey et al. 1993). The incidence rates of chronic bronchitis 
presented in the Seventh-Day Adventist Cohort Study (approximately 6 per 1000 annually 
among non-smokers among individuals over the age of 25) (Abbey et al. 1995) are much 
higher than the COPD incidence estimated for industrialized nations for the WHO 
(approximately 2 per 1000 annually among all individuals over the age of 30) (Lopez et al. 
2006; Shibuya et al. 2001) considering that most COPD is attributed to smoking (Hnizdo et 
al. 2002; Salvi and Barnes 2009). Hofstetter (1998) proposes a very conservative disability 
weight to assign to chronic bronchitis—0.05 per incident case (over a 40-year duration)—
compared to that used by the WHO in the 2000 Global Burden of Disease (0.17 for mild/
moderate COPD and 0.53 for severe COPD) (Mathers et al. 2006a). In Appendix Table 8, 
we applied the more conservative severity factor to the Seventh-Day Adventist Cohort Study 
effect estimate associated with the high chronic bronchitis incidence rate among non-
smokers. The 41 additional YLDs due to PM estimated in the Appendix Table 8 effect factor 
are higher than the 4 YLDs estimated in Table 1 which used our simplified severity factor 
calculation. The burden of chronic bronchitis due to PM may be higher than we account for 
in our simplified severity factor calculation, but the uncertainty in directly attempting to 
estimate the PM-associated burden of chronic bronchitis from the Seventh-Day Adventist 
Cohort Study is large, so we do not use the effect factors in Appendix Table 8 in our final 
characterization factor.
Table 8





























Chronic mortality 5.76 Van Zelm et al. 
(2008) (RR based 
on Künzli et al. 




10 Van Zelm et al. 
(2008) (based on 
Künzli et al. 
(2000) and Pye 
and Watkiss 
(2005)) Note 
that Bare et al. 
(2003) uses 10.9 
DALY/case 
based on De 
Hollander et al. 
(1999)
57.6 Van Zelm 










Acute respiratory morbidity 0.73 Van Zelm et al. 
(2008) (RR based 
on Medina et al. 
(2005) and Finc on 
0.025 Van Zelm et al. 
(2008) (based on 
Knol and 
Staatsen (2005))
0.018 Van Zelm 
et al. (2008)
0.030
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Knol and Staatsen 
(2005))
Acute cardiovascular morbidity 0.55 Van Zelm et al. 
(2008) (RR based 
on Le Tertre et al. 
(2002) and Finc on 
Knol and Staatsen 
(2005))
0.027 Van Zelm et al. 
(2008) (based on 
Knol and 
Staatsen (2005))
0.015 Van Zelm 
et al. (2008)
0.025
Chronic bronchitis (adults) 9.5 Künzli et al. 
(2000)
2 Hofstetter (1998) 19 31.7
Chronic bronchitis (children) 140 Künzli et al. 
(2000)
0.025 Hofstetter (1998) 3.6 6.0
Restricted activity days 6100 Künzli et al. 
(2000)
2.7E-4 Hofstetter (1998) 1.7 2.8
Asthmatics: asthma attacks 
(children)
56 Künzliet al. (2000) 2.7E-4 Hofstetter (1998) 0.015 0.025
Asthmatics: asthma attacks 
(adults)
140 Künzli et al. 
(2000)
2.7E-4 Hofstetter (1998) 0.037 0.062
1
PM2.5 was assumed to be 1.67 times as toxic as PM10 (European Commission 2005).
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Processes for estimating 1) a characterization factor (CF), 2) burden of disease based on 
observed air concentrations and 3) burden of disease based on emissions for PM2.5.
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Intake of PM2.5 (kg) based on emissions vs. intake based on ambient concentrations for each 
county plotted on a log scale to visualize the associations in the counties with lower burdens. 
The solid line is the 1:1 line, and the dotted lines are 10:1 lines.
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Table 1
Characterization factor inputs: Means and ranges (minimum, maximum) for PM2.5 concentration; total, non-
PM and PM2.5-attributable mortality rates; attributable fractions; concentration-response factors; dose-
response factors; severity factors and effect factors standardized to the World Health Organization (WHO) 
World Standard Population.
Cardiopulmonary Lung cancer Cardiopulmonary 
and lung cancer
All causes
PM2.5 concentration (μg/m3), 1979-1983a 21.2 (10.3-37.8)
Total annual mortality rates, 1982-1988a,b,c 640 (520-770) 82 (40-110) 720 (580-870) 1,200 (1,100- 1,400)
Attributable fractionsa,b 0.12 (0.064-0.19) 0.086 (0.042- 0.15) 0.12 (0.063-0.19) 0.079 (0.041- 0.13)
Non-PM mortality ratesa,b,c 560 (480-660) 75 (37-100) 640 (540-740) 1,100 (980- 1,300)
PM2.5-attributable mortality ratesa,b,c 78 (39-150) 7.1 (2.6-15) 86 (42-160) 96 (47-180)
Concentration-response factor (mortality rate 
per μg/m3 PM2.5 inhaled)a,c,d
1.8 (1.6-2.1) 0.17 (0.085-0.24) 2.0 (1.7-2.3) 2.2 (2.0-2.6)
Dose-response factor (deaths per kg PM2.5 
inhaled)a,d
3.9 (3.3-4.4) 0.35 (0.18-0.50) 4.2 (3.6-4.8) 4.7 (4.2-5.5)
Severity Factorse
DALY/death 17 28 19 23f
YLL/death 13 27 15 17f
Effect Factorsd
DALY per kg PM2.5 inhaled 65 9.7 78 110
YLL per kg PM2.5 inhaled 50 9.6 64 82
a
Weighted by the total population of the Standard Metropolitan Statistical Area (N = 63).
b




Denominator is population among or quantity of PM2.5 inhaled by all ages, not just individuals 30 and older.
e
Based on the Global Burden of Disease 2010 Estimates of Deaths, DALY and YLL for the High-Income North America region. YLD = DALY – 
YLL.
f
The age-specific severity factors for the “cardiopulmonary and lung cancer” category were used to calculate the all-cause severity factors. The all-
causes severity factors differ from the “cardiopulmonary and lung cancer” severity factors in this table because of the difference in age distribution 
of all-cause deaths vs. cardiopulmonary and lung cancer deaths.
See Appendix B Tables 5 and 6 for age-group specific results.
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